Posters

Effect of intravitreal ranibizumab, aflibercept and dexamethasone on corneal astigmatism

Poster Details

First Author: S.Kerci TURKEY

Co Author(s):    O. Karti   M. Zengin                          

Abstract Details



Purpose:

To evaluate surgically induced astigmatism after an intravitreal ranibizumab (IVR), aflibercept (IVA) and dexamethasone (IVD) injection.

Setting:

prospective study

Methods:

Sixty eyes of 60 patients who underwent IVR (34 patients) , IVA (16 patients) and IVD (10 patients) injection due to age-related macular degeneration (wet form) or macular edema were included in this study. Patients' pre- and postoperative detailed ophthalmologic examinations were done and topographic keratometric values (K1, K2) were noted. Pre- and postoperative measurements were compared.

Results:

The mean preoperative astigmatism of IVR, IVA and IVD groups were found to be K1; 43.20 ± 1.45 D, K2; 44.25 ± 1.61 D, K1; 42.96 ± 1.46 D, K2; 43.90 ± 1.29 D and K1; 43.00 ± 1.21 D, K2; 43.77 ± 1.12 D, respectively. The mean postoperative asitgmatism of these groups were K1:43.03 ± 1.55 D, K2:44.28 ± 1.70 D in IVR group, K1:43.01 ± 1.50 D, K2:43.96 ± 1.35 D in IVA group and K1: 42.91 ± 1.29 D, K2: 43.83 ± 1.22 D in IVD group, respectively. The difference between preoperative and postoperative K values in three groups was not statistically significant (ranibizumab p1=0.322, p2=0.344; aflibercept p1=0.464, p2=0.447; dexamethasone p1=0.444, p2=0.460).

Conclusions:

Intravitreal injection is a minimally invasive ophthalmologic procedure. Therefore; it doesn’t cause statistically significant induced astigmatism.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy